The Korean Journal of Medicine

  • 제82권6호
  • /
  • Pages.658-666
  • /
  • 2012
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

말기 심부전의 비약물적 치료

Treatment of Advanced Heart Failure: Beyond Medical Treatment

  • 최진오 (성균관대학교 의과대학 삼성서울병원 순환기내과)
  • Choi, Jin-Oh (Division of Cardiology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 발행 : 2012.06.01
⟨ 이전 논문 다음 논문 ⟩

초록

During last 2 decades, advance in the mechanical circulatory support has altered the management of end-stage heart failure and cardiogenic shock. This includes percutaneous mechanical support devices such as extracorporeal membrane oxygenator (ECMO) and implantable left ventricular assist devices (LVAD). Percutaneous devices may provide prompt circulatory support and save lives of the patients with cardiogenic shock. But for a prolonged support, long-term devices such as implantable LVAD are mandatory. LVAD is useful for both bridge-to-transplantation strategy and destination therapy for the patients with end-stage heart failure. Newer LVAD using continuous flow pump has several advantages over those with pulsatile flow pump, which includes smaller size and durability and showed better outcome in recent studies. In this manuscript, brief reviews of percutaneous and implantable devices for the management of advanced heart failure will be provided.

키워드

참고문헌

  1. Fonarow GC, Albert NM, Curtis AB, et al. Associations between outpatient heart failure process-of-care measures and mortality. Circulation 2011;123:1601-1610. https://doi.org/10.1161/CIRCULATIONAHA.110.989632
  2. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS): the CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-1435. https://doi.org/10.1056/NEJM198706043162301
  3. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure: the SOLVD Investigators. N Engl J Med 1991;325:293-302. https://doi.org/10.1056/NEJM199108013250501
  4. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions: the SOLVD Investigattors. N Engl J Med 1992;327:685-691. Erratum in: N Engl J Med 1992;327:1768. https://doi.org/10.1056/NEJM199209033271003
  5. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-2007. https://doi.org/10.1016/S0140-6736(99)04440-2
  6. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13. https://doi.org/10.1016/S0140-6736(98)11181-9
  7. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-237. Erratum in: N Engl J Med 2005;352:2146. https://doi.org/10.1056/NEJMoa043399
  8. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-1549. https://doi.org/10.1056/NEJMoa050496
  9. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-1658. https://doi.org/10.1056/NEJM200105313442201
  10. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: randomized aldactone avaluation study investigators. N Engl J Med 1999;341:709-717. https://doi.org/10.1056/NEJM199909023411001
  11. Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287:1541-1547. https://doi.org/10.1001/jama.287.12.1541
  12. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202. https://doi.org/10.1016/S0140-6736(02)09455-2
  13. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32-43. https://doi.org/10.1056/NEJMoa1100171
  14. McMurray JJ, Teerlink JR, Cotter G, et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007;298:2009-2019. https://doi.org/10.1001/jama.298.17.2009
  15. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1-e90. https://doi.org/10.1016/j.jacc.2008.11.013
  16. Stewart GC, Givertz MM. Mechanical circulatory support for advanced heart failure: patients and technology in evolution. Circulation 2012;125:1304-1315. https://doi.org/10.1161/CIRCULATIONAHA.111.060830
  17. Kar B, Basra SS, Shah NR, Loyalka P. Percutaneous circulatory support in cardiogenic shock: interventional bridge to recovery. Circulation 2012;125:1809-1817. https://doi.org/10.1161/CIRCULATIONAHA.111.040220
  18. Kantrowitz A, Tjonneland S, Freed PS, Phillips SJ, Butner AN, Sherman JL Jr. Initial clinical experience with intraaortic balloon pumping in cardiogenic shock. JAMA 1968;203:113-118. https://doi.org/10.1001/jama.1968.03140020041011
  19. Sanborn TA, Sleeper LA, Bates ER, et al. Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry: should we emergently revascularize occluded coronaries for cardiogenic shock? J Am Coll Cardiol 2000;36(3 Suppl A):1123-1129. https://doi.org/10.1016/S0735-1097(00)00875-5
  20. Barron HV, Every NR, Parsons LS, et al. The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. Am Heart J 2001;141:933-939. https://doi.org/10.1067/mhj.2001.115295
  21. Trost JC, Hillis LD. Intra-aortic balloon counterpulsation. Am J Cardiol 2006;97:1391-1398. https://doi.org/10.1016/j.amjcard.2005.11.070
  22. Gold HK, Leinbach RC, Sanders CA, Buckley MJ, Mundth ED, Austen WG. Intraaortic balloon pumping for ventricular septal defect or mitral regurgitation complicating acute myocardial infarction. Circulation 1973;47:1191-1196. https://doi.org/10.1161/01.CIR.47.6.1191
  23. Loisance DY, Cachera JP, Poulain H, Aubry P, Juvin AM, Galey JJ. Ventricular septal defect after acute myocardial infarction: early repair. J Thorac Cardiovasc Surg 1980;80: 61-67.
  24. Gunstensen J, Goldman BS, Scully HE, Huckell VF, Adelman AG. Evolving indications for preoperative intraaortic balloon pump assistance. Ann Thorac Surg 1976;22:535-545. https://doi.org/10.1016/S0003-4975(10)64472-4
  25. Christenson JT, Simonet F, Badel P, Schmuziger M. Evaluation of preoperative intra-aortic balloon pump support in high risk coronary patients. Eur J Cardiothorac Surg 1997;11: 1097-1103. https://doi.org/10.1016/S1010-7940(97)00087-0
  26. Champsaur G, Ninet J, Vigneron M, Cochet P, Neidecker J, Boissonnat P. Use of the Abiomed BVS System 5000 as a bridge to cardiac transplantation. J Thorac Cardiovasc Surg 1990;100:122-128.
  27. Dekkers RJ, FitzGerald DJ, Couper GS. Five-year clinical experience with Abiomed BVS 5000 as a ventricular assist device for cardiac failure. Perfusion 2001;16:13-18. https://doi.org/10.1177/026765910101600103
  28. De Robertis F, Birks EJ, Rogers P, Dreyfus G, Pepper JR, Khaghani A. Clinical performance with the Levitronix Centrimag short-term ventricular assist device. J Heart Lung Transplant 2006;25:181-186. https://doi.org/10.1016/j.healun.2005.08.019
  29. Doll N, Kiaii B, Borger M, et al. Five-year results of 219 consecutive patients treated with extracorporeal membrane oxygenation for refractory postoperative cardiogenic shock. Ann Thorac Surg 2004;77:151-157. https://doi.org/10.1016/S0003-4975(03)01329-8
  30. Sheu JJ, Tsai TH, Lee FY, et al. Early extracorporeal membrane oxygenator-assisted primary percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST-segment elevation myocardial infarction complicated with profound cardiogenic shock. Crit Care Med 2010;38: 1810-1817. https://doi.org/10.1097/CCM.0b013e3181e8acf7
  31. Choi JO, Yun SH, Sung K, et al. Thioredoxin, adiponectin and clinical course of acute fulminant myocarditis. Heart 2011;97:1067-1073. https://doi.org/10.1136/hrt.2010.219568
  32. Maejima Y, Yasu T, Kubo N, et al. Long-term prognosis of fulminant myocarditis rescued by percutaneous cardiopulmonary support device. Circ J 2004;68:829-833. https://doi.org/10.1253/circj.68.829
  33. Gariboldi V, Grisoli D, Tarmiz A, et al. Mobile extracorporeal membrane oxygenation unit expands cardiac assist surgical programs. Ann Thorac Surg 2010;90:1548-1552. https://doi.org/10.1016/j.athoracsur.2010.06.091
  34. Arlt M, Philipp A, Voelkel S, et al. Hand-held minimised extracorporeal membrane oxygenation: a new bridge to recovery in patients with out-of-centre cardiogenic shock. Eur J Cardiothorac Surg 2011;40:689-694.
  35. Jung C, Schlosser M, Figulla HR, Ferrari M. Providing macro- and microcirculatory support with the Lifebridge System during high-risk PCI in cardiogenic shock. Heart Lung Circ 2009;18:296-298. https://doi.org/10.1016/j.hlc.2008.05.601
  36. Cofer BR, Warner BW, Stallion A, Ryckman FC. Extracorporeal membrane oxygenation in the management of cardiac failure secondary to myocarditis. J Pediatr Surg 1993;28: 669-672. https://doi.org/10.1016/0022-3468(93)90028-J
  37. Ko WJ, Hsu HH, Tsai PR. Prolonged extracorporeal membrane oxygenation support for acute respiratory distress syndrome. J Formos Med Assoc 2006;105:422-426. https://doi.org/10.1016/S0929-6646(09)60140-6
  38. Burkhoff D, Cohen H, Brunckhorst C, O'Neill WW; TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J 2006;152:469.
  39. Thiele H, Sick P, Boudriot E, et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 2005;26:1276-1283. https://doi.org/10.1093/eurheartj/ehi161
  40. Bruckner BA, Jacob LP, Gregoric ID, et al. Clinical experience with the TandemHeart percutaneous ventricular assist device as a bridge to cardiac transplantation. Tex Heart Inst J 2008;35:447-450.
  41. Gregoric ID, Jacob LP, La Francesca S, et al. The TandemHeart as a bridge to a long-term axial-flow left ventricular assist device (bridge to bridge). Tex Heart Inst J 2008;35:125-129.
  42. Brinkman WT, Rosenthal JE, Eichhorn E, et al. Role of a percutaneous ventricular assist device in decision making for a cardiac transplant program. Ann Thorac Surg 2009;88: 1462-1466. https://doi.org/10.1016/j.athoracsur.2009.07.015
  43. Chandra D, Kar B, Idelchik G, et al. Usefulness of percutaneous left ventricular assist device as a bridge to recovery from myocarditis. Am J Cardiol 2007;99:1755-1756. https://doi.org/10.1016/j.amjcard.2007.01.067
  44. Seyfarth M, Sibbing D, Bauer I, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol 2008;52:1584-1588. https://doi.org/10.1016/j.jacc.2008.05.065
  45. Rajagopal V, Steahr G, Wilmer CI, Raval NY. A novel percutaneous mechanical biventricular bridge to recovery in severe cardiac allograft rejection. J Heart Lung Transplant 2010;29:93-95. https://doi.org/10.1016/j.healun.2009.09.015
  46. Wiktor DM, Sawlani N, Kanthi Y, Sipahi I, Fang JC, Blitz A. Successful combined use of Impella Recover 2.5 device and intra-aortic balloon pump support in cardiogenic shock from acute myocardial infarction. ASAIO J 2010;56:519-521. https://doi.org/10.1097/MAT.0b013e3181f7478e
  47. Portner PM, Oyer PE, Pennington DG, et al. Implantable electrical left ventricular assist system: bridge to transplantation and the future. Ann Thorac Surg 1989;47:142-150. https://doi.org/10.1016/0003-4975(89)90256-7
  48. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001;345:1435-1443. https://doi.org/10.1056/NEJMoa012175
  49. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009;361:2241-2251. https://doi.org/10.1056/NEJMoa0909938
  50. Miller LW, Pagani FD, Russell SD, et al. Use of a continuousflow device in patients awaiting heart transplantation. N Engl J Med 2007;357:885-896. https://doi.org/10.1056/NEJMoa067758
  51. Stewart GC, Stevenson LW. Keeping left ventricular assist device acceleration on track. Circulation 2011;123:1559-1568. https://doi.org/10.1161/CIRCULATIONAHA.110.982512
  52. Stehlik J, Feldman DS. 2011-2020: decade of the ventricular assist device. Curr Opin Cardiol 2011;26:230-231. https://doi.org/10.1097/HCO.0b013e328345c868
  53. Kirklin JK, Naftel DC, Kormos RL, et al. Third INTERMACS annual report: the evolution of destination therapy in the United States. J Heart Lung Transplant 2011;30:115-123. https://doi.org/10.1016/j.healun.2010.12.001
  54. Pagani FD, Miller LW, Russell SD, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol 2009;54:312-321. https://doi.org/10.1016/j.jacc.2009.03.055
  55. Starling RC, Naka Y, Boyle AJ, et al. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 2011; 57:1890-1898. https://doi.org/10.1016/j.jacc.2010.10.062
  56. Fang JC. Rise of the machines: left ventricular assist devices as permanent therapy for advanced heart failure. N Engl J Med 2009;361:2282-2285. https://doi.org/10.1056/NEJMe0910394
  57. Cowger J, Pagani FD, Haft JW, Romano MA, Aaronson KD, Kolias TJ. The development of aortic insufficiency in left ventricular assist device-supported patients. Circ Heart Fail 2010;3:668-674. https://doi.org/10.1161/CIRCHEARTFAILURE.109.917765
  58. Wilson SR, Mudge GH Jr, Stewart GC, Givertz MM. Evaluation for a ventricular assist device: selecting the appropriate candidate. Circulation 2009;119:2225-2232. https://doi.org/10.1161/CIRCULATIONAHA.109.850610
  59. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report: 2010. J Heart Lung Transplant 2010;29:1089-1103. https://doi.org/10.1016/j.healun.2010.08.007
  60. John R, Pagani FD, Naka Y, et al. Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: impact of duration of left ventricular assist device support and other variables. J Thorac Cardiovasc Surg 2010;140:174-181. https://doi.org/10.1016/j.jtcvs.2010.03.037
  61. Zierer A, Melby SJ, Voeller RK, et al. Late-onset driveline infections: the Achilles' heel of prolonged left ventricular assist device support. Ann Thorac Surg 2007;84:515-520. https://doi.org/10.1016/j.athoracsur.2007.03.085
  62. Holman WL, Pamboukian SV, McGiffin DC, Tallaj JA, Cadeiras M, Kirklin JK. Device related infections: are we making progress? J Card Surg 2010;25:478-483. https://doi.org/10.1111/j.1540-8191.2010.01034.x
  63. Letsou GV, Shah N, Gregoric ID, Myers TJ, Delgado R, Frazier OH. Gastrointestinal bleeding from arteriovenous malformations in patients supported by the Jarvik 2000 axial-flow left ventricular assist device. J Heart Lung Transplant 2005;24:105-109. https://doi.org/10.1016/j.healun.2003.10.018
  64. Crow S, John R, Boyle A, et al. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg 2009;137:208-215. https://doi.org/10.1016/j.jtcvs.2008.07.032
  65. Uriel N, Pak SW, Jorde UP, et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol 2010;56:1207-1213. https://doi.org/10.1016/j.jacc.2010.05.016
  66. Meyer AL, Malehsa D, Bara C, et al. Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device. Circ Heart Fail 2010;3:675-681. https://doi.org/10.1161/CIRCHEARTFAILURE.109.877597
  67. Mancini D, Lietz K. Selection of cardiac transplantation candidates in 2010. Circulation 2010;122:173-183. https://doi.org/10.1161/CIRCULATIONAHA.109.858076
  68. Wilson SR, Givertz MM, Stewart GC, Mudge GH Jr. Ventricular assist devices the challenges of outpatient management. J Am Coll Cardiol 2009;54:1647-1659. https://doi.org/10.1016/j.jacc.2009.06.035
  69. Baldwin JT, Mann DL. NHLBI's program for VAD therapy for moderately advanced heart failure: the REVIVE-IT pilot trial. J Card Fail 2010;16:855-858. https://doi.org/10.1016/j.cardfail.2010.06.414

피인용 문헌

  1. Percutaneous left ventricular assist device: a systematic review vol.57, pp.11, 2012, https://doi.org/10.5124/jkma.2014.57.11.949
  2. 만성 심부전 환자의 스마트폰을 활용한 자가관리에 대한 인식 : 포커스 그룹 인터뷰 적용 vol.16, pp.9, 2018, https://doi.org/10.14400/jdc.2018.16.9.319
  3. Unplanned readmission of patients with heart transplantation in 1 year: A retrospective study vol.76, pp.3, 2012, https://doi.org/10.1111/jan.14280